SSelectStock
Sign in

GUFICBIOGufic Biosciences Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

393.75
3.10%
70Decent

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)3,948.60
P/E61.33
P/B5.95
PEG0.33
ROE %10.14
ROCE %11.30
Debt / Equity0.61
EPS6.42
Revenue Growth %22.80
Profit Growth %183.10
Dividend Yield %0.03
Promoter Holding %77.55
FII Holding %3.68
DII Holding %
Beta-0.04

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG80%393.75378.30463.454.51
HOLDConviction 74%

The picture

  • Revenue growth: 22.8% YoY
  • Profit growth: 183.1% YoY
  • Debt/Equity: 0.61
  • RSI: 58
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 80%)

Bull case

  • Revenue growth: 22.8% YoY
  • Profit growth: 183.1% YoY
  • Debt/Equity: 0.61
  • RSI: 58

Bear case

  • ROE: 10.1%
  • Valuation vs sector: P/E 61.3 vs sector 38.6
  • MACD: bearish
  • Volume: 0.1x 20-day average

Key risks

  • ROE: 10.1%
  • Valuation vs sector: P/E 61.3 vs sector 38.6

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹393.75
Stop Loss
₹354.52
risk 10%
Target 1 (1.5R)
₹452.60
+14.9%
Target 2 (3R)
₹511.44
+29.9%
Support (20d)
₹358.10
Resistance (52w)
₹448.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹39.23/share
ATR (volatility)
₹16.88
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹16.88). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
67
Technical
69
Momentum
84
Risk (safety)
55

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.